Symrise announces today a strategic equity investment in Cellibre, a U.S.-based biotechnology company specializing in sustainable biomanufacturing. This partnership positions Symrise at the forefront of fermentation-derived ingredients that are better for both people and planet. It will initially focus on innovation across taste solutions and cosmetic actives, reinforcing its long-term competitiveness and sustainability leadership.
By partnering with Cellibre, Symrise gains preferred access to proprietary, fermentation-based technology, enabling scalable production of high-value ingredients across food, beverage, cosmetics, and nutraceutical sectors. With this investment, Symrise will leverage Cellibre’s world-class biotechnology platform to enable a more resilient supply chain, mitigating seasonal and cultivation variability.
"This investment accelerates our biotechnology roadmap and strengthens our ability to deliver sustainable, high-quality solutions to our customers. Together with Cellibre, we will combine scientific expertise with application know-how and market reach to unlock new growth opportunities," says Imke Meyer, Project Lead for Biotechnology at Symrise.
Cellibre brings a significant track record in designing and engineering microorganisms for the production of cultured natural products and chemicals that are utilized in pharmaceuticals, functional health, beauty ingredients, industrial applications, and more.
"Since 2017, we have been led by the belief that biology is the future of manufacturing and we are committed to creating more resilient supply chains, delivering products that are lower cost and higher quality while limiting the impact on natural ecosystems.", says Ben Chiarelli, CEO of Cellibre. "This partnership represents another external validation of our approach, technology, and team, and will leverage the Symrise team’s global market access and deep expertise in flavors, fragrances and cosmetics — creating powerful synergies for both companies."
This collaboration supports Symrise’s ambition to integrate biotechnology across its operations, ensuring long-term resilience, portfolio diversification, and competitive advantage. It also aligns with the company’s sustainability commitments and consumer-driven innovation strategy.
